Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-mesothelin KIR-CAR-transduced T cells SynKIR-110

A preparation of autologous T lymphocytes that have been genetically modified to express a killer cell immunoglobulin-like receptor (KIR)-based chimeric antigen receptor (CAR) consisting of an anti-mesothelin (MSLN) single chain variable fragment (scFv) fused to the transmembrane and cytoplasmic domains of the stimulatory KIR 2DS2 (KIR2DS2), and the immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor protein and costimulatory chain DAP12, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MSLN KIR-CAR-transduced T cells SynKIR-110 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a tumor-associated antigen (TAA) and cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. KIR is normally expressed by natural killer (NK) cells, and KIR-based CAR may decrease T-cell exhaustion and enhance T-cell persistence.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-mesothelin KIR-CAR-expressing T cells SynKIR-110
autologous anti-MSLN KIR-CAR-transduced T cells SynKIR-110
Code name:SynKIR 110
SynKIR-110
SynKIR110
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search